Publikationen (106) Publikationen von ROSA MARÍA AYALA DÍAZ

2024

  1. Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges

    Frontiers in Immunology, Vol. 15

  2. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens?

    Annals of Hematology, Vol. 103, Núm. 8, pp. 2845-2851

  3. Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry

    Cancer, Vol. 130, Núm. 20, pp. 3436-3451

  4. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

    Leukemia

  5. Real-World Impact of Deep Targeted Sequencing on Erythrocytosis and Thrombocytosis Diagnosis: A Reference Centre Experience

    Cancers, Vol. 16, Núm. 18

  6. Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry

    Haematologica

2023

  1. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

    Hematological oncology

  2. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

    JCI Insight, Vol. 8, Núm. 2

  3. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

    Blood Advances, Vol. 7, Núm. 9, pp. 1672-1681

  4. Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure

    Life, Vol. 13, Núm. 9

  5. Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma (Journal of Hematology & Oncology, (2023), 16, 1, (76), 10.1186/s13045-023-01474-w)

    Journal of Hematology and Oncology

  6. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients

    Frontiers in immunology

  7. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients (Frontiers in Immunology, (2023), 14, (1188818), 10.3389/fimmu.2023.1188818)

    Frontiers in Immunology

  8. Large-scale real-life analysis of survival and usage of therapies in multiple myeloma

    Journal of Hematology and Oncology

  9. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

    The Lancet, Vol. 401, Núm. 10373, pp. 269-280

  10. Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE

    Frontiers in Pharmacology, Vol. 14

  11. Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia

    Leukemia, Vol. 37, Núm. 8, pp. 1649-1659

  12. Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT

    Leukemia, Vol. 37, Núm. 3, pp. 659-669

  13. Should we move to a genomic classification of neutrophilic myeloid neoplasms?

    Blood Advances

  14. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

    British Journal of Haematology